• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雾化 PLA 和 PLGA 纳米粒增强乙型肝炎疫苗的体液、黏膜和细胞因子应答。

Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.

机构信息

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, 1300 Coulter, Amarillo, Texas 79106, USA.

出版信息

Mol Pharm. 2011 Apr 4;8(2):405-15. doi: 10.1021/mp100255c. Epub 2011 Jan 11.

DOI:10.1021/mp100255c
PMID:21189035
Abstract

Porous poly(L-lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles were tested for pulmonary delivery of hepatitis B vaccine. In particular, the effects of particle size and hydrophobicity on mucosal and cell-mediated immune responses were investigated. Three formulations of PLA and PLGA nanoparticles containing a fixed amount of hepatitis B surface antigen (HBsAg) were prepared by a double-emulsion-solvent-evaporation method and characterized for surface morphology, charge, size, density and in vitro release. The immune responses were studied by measuring secretory IgA levels in mucosal fluids and quantitating cytokine levels in rat spleen homogenates. Particle uptake was studied in rat alveolar macrophages. Scanning electron microscopy revealed particles with smooth surfaces. Zeta potential measurements indicated that the particles carried negative surface charges. The antigen was continuously released for 42 days in phosphate buffer. Hydrophobic particles >500 nm elicited a more robust increase in secretary IgA, interleukin-2 and interferon-γ levels compared to hydrophilic particles <500 nm. Large hydrophobic particles were more efficiently internalized by rat alveolar macrophages compared to smaller hydrophilic particles. Calu-3 cell viability studies indicate that the viability of cells is not affected by nanoparticulate formulations. This study demonstrates that inhalable nanoparticles of HBsAg produce an enhancement of immune responses.

摘要

多孔聚(L-丙交酯)(PLA)和聚(丙交酯-乙交酯)(PLGA)纳米粒子被测试用于乙型肝炎疫苗的肺部递送。特别是,研究了粒径和疏水性对黏膜和细胞介导的免疫应答的影响。通过双乳液-溶剂蒸发法制备了三种含有固定量乙型肝炎表面抗原(HBsAg)的 PLA 和 PLGA 纳米粒子制剂,并对其表面形态、电荷、粒径、密度和体外释放进行了表征。通过测量黏膜液中分泌型 IgA 水平和定量大鼠脾匀浆中细胞因子水平来研究免疫反应。研究了颗粒摄取在大鼠肺泡巨噬细胞中的作用。扫描电子显微镜显示颗粒表面光滑。Zeta 电位测量表明颗粒带有负表面电荷。抗原在磷酸盐缓冲液中持续释放 42 天。与<500nm 的亲水性颗粒相比,>500nm 的疏水性颗粒引起的分泌型 IgA、白细胞介素-2 和干扰素-γ水平的增加更为显著。与较小的亲水性颗粒相比,大鼠肺泡巨噬细胞更有效地摄取大的疏水性颗粒。Calu-3 细胞活力研究表明,纳米颗粒制剂不会影响细胞活力。本研究表明,可吸入的 HBsAg 纳米颗粒可增强免疫应答。

相似文献

1
Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine.雾化 PLA 和 PLGA 纳米粒增强乙型肝炎疫苗的体液、黏膜和细胞因子应答。
Mol Pharm. 2011 Apr 4;8(2):405-15. doi: 10.1021/mp100255c. Epub 2011 Jan 11.
2
Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.重组乙型肝炎表面抗原PLGA颗粒的表面电荷对增强全身和黏膜免疫反应的影响。
Int J Pharm. 2009 Sep 8;379(1):41-50. doi: 10.1016/j.ijpharm.2009.06.006. Epub 2009 Jun 12.
3
Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.粒径影响以可吸入颗粒形式配制的乙肝疫苗所产生的免疫应答。
Pharm Res. 2010 May;27(5):905-19. doi: 10.1007/s11095-010-0094-x. Epub 2010 Mar 16.
4
Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.对经鼻给予的含有重组乙型肝炎抗原的表面修饰聚乳酸-羟基乙酸共聚物(PLGA)微球产生强烈的全身和黏膜免疫反应。
Vaccine. 2006 May 8;24(19):4201-11. doi: 10.1016/j.vaccine.2006.01.011. Epub 2006 Jan 18.
5
Immunological evaluation of colonic delivered Hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles.经结肠递送的负载乙型肝炎表面抗原的Toll样受体4激动剂修饰固体脂肪纳米粒的免疫学评价
Int Immunopharmacol. 2016 Oct;39:343-352. doi: 10.1016/j.intimp.2016.08.007. Epub 2016 Aug 13.
6
Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.比较含重组乙型肝炎抗原的阳离子 PLGA 微球的体液和细胞介导免疫反应。
Int J Pharm. 2011 Apr 15;408(1-2):50-7. doi: 10.1016/j.ijpharm.2011.01.045. Epub 2011 Feb 1.
7
Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.用于鼻腔疫苗递送的表面改性聚乳酸-羟基乙酸共聚物纳米颗粒的研制与表征:粘膜粘附性包衣对抗原摄取和免疫佐剂活性的影响
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):550-9. doi: 10.1016/j.ejpb.2013.06.017. Epub 2013 Jul 4.
8
Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.基于单剂量稳定化聚(D,L-丙交酯-乙交酯)微球的乙型肝炎疫苗的研发。
J Pharm Pharmacol. 2004 Oct;56(10):1243-50. doi: 10.1211/0022357044418.
9
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.使用四流体喷嘴喷雾干燥器一步制备含利福平/聚乳酸-羟基乙酸共聚物纳米颗粒的甘露醇微球用于肺结核吸入治疗
J Control Release. 2009 Apr 2;135(1):19-24. doi: 10.1016/j.jconrel.2008.11.027. Epub 2008 Dec 7.
10
Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B.基于凝集素的 PLGA 纳米粒用于口服黏膜免疫接种乙型肝炎。
J Drug Target. 2011 Jan;19(1):67-78. doi: 10.3109/10611861003733946. Epub 2010 Mar 25.

引用本文的文献

1
Targeting Immune Cells.靶向免疫细胞。
J Aerosol Med Pulm Drug Deliv. 2024 Dec;37(6):328-337. doi: 10.1089/jamp.2024.63954.es.
2
PEI-Engineered Lipid@PLGA Hybrid Nanoparticles for Multimodal Delivery of Antigens and Immune Adjuvants to the Respiratory Mucosa.用于将抗原和免疫佐剂多模式递送至呼吸道黏膜的聚乙二醇化聚乙烯亚胺工程化脂质@聚乳酸-羟基乙酸共聚物杂化纳米颗粒
Adv Healthc Mater. 2024 Dec;13(32):e2402688. doi: 10.1002/adhm.202402688. Epub 2024 Sep 11.
3
Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.
精准给药中的生物屏障与宿主-材料界面的最新综述:生物材料工程促进更好治疗方法的进展
Pharmaceutics. 2024 Aug 16;16(8):1076. doi: 10.3390/pharmaceutics16081076.
4
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.基于纳米平台的鼻腔内疫苗:当前进展和临床挑战。
ACS Nano. 2024 Sep 10;18(36):24650-24681. doi: 10.1021/acsnano.3c10797. Epub 2024 Aug 26.
5
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection.针对关键进入糖蛋白的鸡尾酒纳米疫苗引发了针对 EBV 感染的高中和抗体水平。
Nat Commun. 2024 Jun 21;15(1):5310. doi: 10.1038/s41467-024-49546-w.
6
Polymeric Nanoparticles for Drug Delivery.高分子纳米粒药物递送系统
Chem Rev. 2024 May 8;124(9):5505-5616. doi: 10.1021/acs.chemrev.3c00705. Epub 2024 Apr 16.
7
Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.纳米技术在防治感染性和炎症性疾病方面的前沿应用:预防与治疗。
Signal Transduct Target Ther. 2024 Feb 21;9(1):34. doi: 10.1038/s41392-024-01745-z.
8
The use of nanoparticles in the treatment of infectious diseases and cancer, dental applications and tissue regeneration: a review.纳米颗粒在传染病和癌症治疗、牙科应用及组织再生中的应用:综述
Front Med Technol. 2024 Jan 23;5:1330007. doi: 10.3389/fmedt.2023.1330007. eCollection 2023.
9
Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus.推进针对新冠病毒疫苗研发的纳米技术平台
Diseases. 2023 Dec 10;11(4):177. doi: 10.3390/diseases11040177.
10
A Glance on Nanovaccine: A Potential Approach for Disease Prevention.纳米疫苗一瞥:疾病预防的潜在方法。
Curr Pharm Biotechnol. 2024;25(11):1406-1418. doi: 10.2174/0113892010254221231006100659.